Mutual Advisors LLC Has $730,000 Holdings in AstraZeneca PLC (NASDAQ:AZN)

Mutual Advisors LLC lessened its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 5.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,908 shares of the company’s stock after selling 674 shares during the quarter. Mutual Advisors LLC’s holdings in AstraZeneca were worth $730,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in AZN. McClarren Financial Advisors Inc. boosted its holdings in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares during the period. Capital Performance Advisors LLP bought a new stake in shares of AstraZeneca during the third quarter worth approximately $28,000. Albion Financial Group UT boosted its holdings in shares of AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after acquiring an additional 248 shares during the period. Groupama Asset Managment boosted its stake in shares of AstraZeneca by 22.9% in the third quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock valued at $42,000 after buying an additional 101,225 shares during the period. Finally, Ashton Thomas Securities LLC bought a new stake in shares of AstraZeneca in the third quarter valued at approximately $45,000. Institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on AZN. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Stock Up 0.7 %

Shares of AZN opened at $69.06 on Monday. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The company has a market cap of $214.16 billion, a P/E ratio of 33.04, a P/E/G ratio of 1.13 and a beta of 0.46. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The firm has a 50 day simple moving average of $66.44 and a two-hundred day simple moving average of $74.17.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the previous year, the business earned $0.87 earnings per share. The company’s revenue was up 18.0% on a year-over-year basis. Research analysts forecast that AstraZeneca PLC will post 4.12 EPS for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.